| pubmed-article:7397943 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7397943 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:7397943 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7397943 | lifeskim:mentions | umls-concept:C0010934 | lld:lifeskim |
| pubmed-article:7397943 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:7397943 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7397943 | pubmed:dateCreated | 1980-10-27 | lld:pubmed |
| pubmed-article:7397943 | pubmed:abstractText | Actinomycin D is generally administered by serial low-dose injection over 5-10 days. Recent recognition of prolonged serum and tissue half-lives suggests that high-dose intermittent injecton should be equally effective and less toxic. An intermitten single dose schedule was selected for this phase II trial of actinomycin D in 23 patients with advanced breast cancer refractory to standard combination chemotherapy. The drug was given in doses of 0.75-1.5 mg/m2 at 2-week intervals or on days 1 and 8 of 28-day treatment cycles. One patient obtained a partial response with a duration of 5.7 months. Four patients experienced stabilization of advanced disease, with a mean duration of response of 6.4 months. Gastrointestinal toxicity occurred in 47% of patients and mild to moderate myelosuppression in 39%. We conclude that actinomycin D in this dosage and schedule has limited activity in advanced breast cancer. Higher doses might result in increased response rates but would be associated with greater toxicity. | lld:pubmed |
| pubmed-article:7397943 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7397943 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7397943 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7397943 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7397943 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7397943 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:SpurrC LCL | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:CooperM RMR | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:WhiteD RDR | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:RichardsFF2nd | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:MussH BHB | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:StuartJ JJJ | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:JacksonD VDV | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:BarnesP LPL | lld:pubmed |
| pubmed-article:7397943 | pubmed:author | pubmed-author:GrimmR ARA | lld:pubmed |
| pubmed-article:7397943 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7397943 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:7397943 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7397943 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7397943 | pubmed:pagination | 195-7 | lld:pubmed |
| pubmed-article:7397943 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:meshHeading | pubmed-meshheading:7397943-... | lld:pubmed |
| pubmed-article:7397943 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7397943 | pubmed:articleTitle | Actinomycin D in the treatment of advanced breast cancer. | lld:pubmed |
| pubmed-article:7397943 | pubmed:publicationType | Journal Article | lld:pubmed |
